Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity
- PMID: 36308049
- PMCID: PMC9972014
- DOI: 10.1002/cam4.5299
Association between a single nucleotide polymorphism in the R3HCC1 gene and irinotecan toxicity
Abstract
Objective: Irinotecan is a useful anticancer drug for colorectal cancer treatment. UGT1A1*28 and *6 gene polymorphisms are known risk factors for irinotecan-associated toxicity. However, severe adverse effects due to irinotecan have been observed even in patients who do not harbor UGT1A1*28 or *6. We investigated gene polymorphisms in the whole exome to identify useful biomarkers for irinotecan toxicity other than UGT1A.
Methods: A total of 178 patients with metastatic colorectal cancer (mCRC) and 87 patients with pancreatic cancer were treated with FOLFIRI, FOLFOX, FOLFOXIRI, modified FOLFIRINOX, or gemcitabine plus nab-paclitaxel. Genome-wide screening was performed using whole-exome sequencing (WES), and validation analysis was performed using qPCR with a hydrolysis probe.
Results: Using WES after a doublet chemotherapy regimen comprising irinotecan and 5-fluorouracil (n = 15), seven single nucleotide polymorphisms (SNPs) were identified as candidate biomarkers for irinotecan-associated toxicity of neutropenia. Among the seven SNPs, an SNP in R3H domain and coiled-coil containing 1 (R3HCC1; c.919G > A, rs2272761) showed a significant association with neutropenia (>grade 3) after doublet chemotherapy. Patients receiving irinotecan including triplet chemotherapy, FOLFOXIRI for mCRC (n = 23) or modified FOLFIRINOX for pancreatic cancer (n = 40), also showed significant linear trends between R3HCC1 polymorphism and neutropenia (p = 0.017 and 0.046, respectively). No significant association was observed in patients treated with irinotecan-free regimens, FOLFOX for mCRC (n = 66), and gemcitabine plus nab-paclitaxel for pancreatic cancer (n = 47).
Conclusion: Thus, an SNP in the R3HCC1 gene may be a useful biomarker for the toxicity of irinotecan-containing chemotherapy for mCRC and pancreatic cancer.
Keywords: R3HCC1; colorectal cancer; irinotecan; neutropenia; pancreatic cancer.
© 2022 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.
Conflict of interest statement
The authors have no conflicts of interest.
Figures

Similar articles
-
The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer.Cancer Sci. 2025 Jul;116(7):2008-2019. doi: 10.1111/cas.70087. Epub 2025 Apr 26. Cancer Sci. 2025. PMID: 40285634 Free PMC article.
-
UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan.Cancer Sci. 2013 Dec;104(12):1662-9. doi: 10.1111/cas.12283. Epub 2013 Oct 27. Cancer Sci. 2013. PMID: 24033692 Free PMC article. Clinical Trial.
-
Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens.J Pharmacol Exp Ther. 2013 Apr;345(1):95-101. doi: 10.1124/jpet.112.202242. Epub 2013 Feb 5. J Pharmacol Exp Ther. 2013. PMID: 23386248 Free PMC article. Clinical Trial.
-
Meta-analysis examining overall survival in patients with pancreatic cancer treated with second-line 5-fluorouracil and oxaliplatin-based therapy after failing first-line gemcitabine-containing therapy: effect of performance status and comparison with other regimens.BMC Cancer. 2020 Jul 8;20(1):633. doi: 10.1186/s12885-020-07110-x. BMC Cancer. 2020. PMID: 32641104 Free PMC article.
-
Chemotherapy of metastatic colorectal cancer.Prescrire Int. 2010 Oct;19(109):219-24. Prescrire Int. 2010. PMID: 21180382 Review.
Cited by
-
The C11orf24 Gene as a Useful Biomarker for Predicting Severe Neutropenia in Modified FOLFIRINOX for Pancreatic Cancer.Cancer Sci. 2025 Jul;116(7):2008-2019. doi: 10.1111/cas.70087. Epub 2025 Apr 26. Cancer Sci. 2025. PMID: 40285634 Free PMC article.
-
Parallel Toxicities: A Comparative Analysis of Chemotherapy-Induced Neutropenia and Alopecia.Cancers (Basel). 2025 Mar 30;17(7):1163. doi: 10.3390/cancers17071163. Cancers (Basel). 2025. PMID: 40227705 Free PMC article. Review.
-
A Case of Inflammatory Myofibroblastic Tumor in the Abdominal Wall with Anaplastic Lymphoma Kinase and Whole Exome Sequencing Analysis.Surg Case Rep. 2025;11(1):25-0181. doi: 10.70352/scrj.cr.25-0181. Epub 2025 Jul 16. Surg Case Rep. 2025. PMID: 40678018 Free PMC article.
References
-
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7‐34. - PubMed
-
- Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut. 2017;66(4):683‐691. - PubMed
-
- Saltz LB, Clarke S, Diaz‐Rubio E, et al. Bevacizumab in combination with oxaliplatin‐based chemotherapy as first‐line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol. 2008;26(12):2013‐2019. - PubMed
-
- Saltz LB, Cox JV, Blanke C, et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan study group. N Engl J Med. 2000;343(13):905‐914. - PubMed
-
- Tabernero J, Yoshino T, Cohn AL, et al. Ramucirumab versus placebo in combination with second‐line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first‐line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double‐blind, multicentre, phase 3 study. Lancet Oncol. 2015;16(5):499‐508. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases